{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:04Z","timestamp":1793963044266,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41591-025-03885-3","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T09:02:50Z","timestamp":1756976570000},"page":"3492-3503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-2900","authenticated-orcid":false,"given":"Fernanda","family":"Mosele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Corcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Pierotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Le Bescond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-8536","authenticated-orcid":false,"given":"Magali","family":"Lacroix-Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Nachabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Catelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-7664","authenticated-orcid":false,"given":"Bastien","family":"Job","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-6011","authenticated-orcid":false,"given":"Fathia","family":"Mami-Chouaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Badel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-160X","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Farace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Oulhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6050-3457","authenticated-orcid":false,"given":"Patricia","family":"Kannouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4221","authenticated-orcid":false,"given":"Diep T. N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-5324","authenticated-orcid":false,"given":"Nathalie","family":"Droin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Vicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-0561","authenticated-orcid":false,"given":"Jean Sebastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-4032","authenticated-orcid":false,"given":"Veronique","family":"D\u2019Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-9484","authenticated-orcid":false,"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Ducoulombier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Antoine","family":"Benderra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mayeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-3116","authenticated-orcid":false,"given":"Elise","family":"Deluche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Deneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Cheikh-Hussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5767-3912","authenticated-orcid":false,"given":"Pierre","family":"Guyader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Signolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Godefroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-3498","authenticated-orcid":false,"given":"Hugues","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vakalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-1070","authenticated-orcid":false,"given":"Stergios","family":"Christodoulidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Koudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sporchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5649-2650","authenticated-orcid":false,"given":"Fumitaka","family":"Suto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2968","authenticated-orcid":false,"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-8357","authenticated-orcid":false,"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Montagnac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"3885_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3885_CR2","doi-asserted-by":"crossref","first-page":"10528","DOI":"10.1200\/JCO.2023.41.16_suppl.10528","volume":"41","author":"ET Sedeta","year":"2023","unstructured":"Sedeta, E. T., Jobre, B. & Avezbakiyev, B. Breast cancer: global patterns of incidence, mortality, and trends. J. Clin. Oncol. 41, 10528\u201310528 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3885_CR4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.annonc.2023.08.020","volume":"34","author":"F Mosele","year":"2023","unstructured":"Mosele, F., Montagnac, G., Pistilli, B. & Andr\u00e9, F. Optimizing the potential of antibody\u2013drug conjugates in oncology. Ann. Oncol. 34, 964\u2013967 (2023).","journal-title":"Ann. Oncol."},{"key":"3885_CR5","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates, J. T. et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11, 2436\u20132445 (2021).","journal-title":"Cancer Discov."},{"key":"3885_CR6","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters, C. & Brown, S. Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 35, e00225 (2015).","journal-title":"Biosci. Rep."},{"key":"3885_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2020.07.002","volume":"37","author":"E Tarcsa","year":"2020","unstructured":"Tarcsa, E., Guffroy, M. R., Falahatpisheh, H., Phipps, C. & Kalvass, J. C. Antibody-drug conjugates as targeted therapies: are we there yet? A critical review of the current clinical landscape. Drug Discov. Today Technol. 37, 13\u201322 (2020).","journal-title":"Drug Discov. Today Technol."},{"key":"3885_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","volume":"130","author":"EN Hoogenboezem","year":"2018","unstructured":"Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 130, 73\u201389 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3885_CR9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & De Vries, E. G. E. The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"3885_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3885_CR11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785 (2023).","journal-title":"Lancet"},{"key":"3885_CR12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1423\u20131433 (2023).","journal-title":"Lancet"},{"key":"3885_CR13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia, A. et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J. Clin. Oncol. 43, 285\u2013296 (2025).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR14","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 (2023).","journal-title":"Nat. Med."},{"key":"3885_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101378","volume":"8","author":"B Pistilli","year":"2023","unstructured":"Pistilli, B. et al. 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01). ESMO Open 8, 101378 (2023).","journal-title":"ESMO Open"},{"key":"3885_CR16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495 (2021).","journal-title":"Ann. Oncol."},{"key":"3885_CR17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.22.02807","volume":"41","author":"B Moy","year":"2023","unstructured":"Moy, B., Rumble, R. B., Carey, L. A. & Metastatic Breast Cancer Expert Panel. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO Guideline rapid recommendation update. J. Clin. Oncol. 41, 1318\u20131320 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR18","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3885_CR19","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J. Clin. Oncol. 41, 4004\u20134013 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR20","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 29, 1541\u20131547 (2018).","journal-title":"Ann. Oncol."},{"key":"3885_CR21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im, S.-A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N. Engl. J. Med. 381, 307\u2013316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3885_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102786","volume":"129","author":"F Papa","year":"2024","unstructured":"Papa, F. et al. Long road towards effective HER3 targeting in breast cancer. Cancer Treat. Rev. 129, 102786 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"3885_CR23","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop, I. E. et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody\u2013drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial. J. Clin. Oncol. 41, 5550\u20135560 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(92)90307-X","volume":"70","author":"P Van Der Sluijs","year":"1992","unstructured":"Van Der Sluijs, P. et al. The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell 70, 729\u2013740 (1992).","journal-title":"Cell"},{"key":"3885_CR25","doi-asserted-by":"crossref","unstructured":"Bardia A. et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl. J. Med. 391, 2110\u20132122 (2024).","DOI":"10.1056\/NEJMoa2407086"},{"key":"3885_CR26","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"G Curigliano","year":"2024","unstructured":"Curigliano, G. et al. Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06). J. Clin. Oncol. 42, LBA1000 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR27","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2212 and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J. Clin. Oncol. 42, 2281\u20132294 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","volume":"41","author":"RO Abelman","year":"2023","unstructured":"Abelman, R. O. et al. Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. J. Clin. Oncol. 41, 1022 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR29","doi-asserted-by":"crossref","unstructured":"Huppert, L. et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). Cancer Res. 84, abstr. PS08-04 (2024).","DOI":"10.1158\/1538-7445.SABCS23-PS08-04"},{"key":"3885_CR30","doi-asserted-by":"crossref","first-page":"e0267027","DOI":"10.1371\/journal.pone.0267027","volume":"17","author":"K Koyama","year":"2022","unstructured":"Koyama, K. et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS ONE 17, e0267027 (2022).","journal-title":"PLoS ONE"},{"key":"3885_CR31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-013-2485-2","volume":"139","author":"S Thrane","year":"2013","unstructured":"Thrane, S., Lykkesfeldt, A. E., Larsen, M. S., Sorensen, B. S. & Yde, C. W. Estrogen receptor \u03b1 is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER\/ERK signaling. Breast Cancer Res. Treat. 139, 71\u201380 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"3885_CR32","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2848","volume":"13","author":"IR Hutcheson","year":"2011","unstructured":"Hutcheson, I. R. et al. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin \u03b21. Breast Cancer Res. 13, R29 (2011).","journal-title":"Breast Cancer Res."},{"key":"3885_CR33","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/ijc.22423","volume":"120","author":"B Liu","year":"2007","unstructured":"Liu, B. et al. Downregulation of erbB3 abrogates erbB2\u2010mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer 120, 1874\u20131882 (2007).","journal-title":"Int. J. Cancer"},{"key":"3885_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50056-y","volume":"15","author":"F Bras\u00f3-Maristany","year":"2024","unstructured":"Bras\u00f3-Maristany, F. et al. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nat. Commun. 15, 5826 (2024).","journal-title":"Nat. Commun."},{"key":"3885_CR35","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson, N. & Ablasser, A. The cGAS\u2013STING pathway and cancer. Nat. Cancer 3, 1452\u20131463 (2022).","journal-title":"Nat. Cancer"},{"key":"3885_CR36","volume":"22","author":"K-S Oh","year":"2024","unstructured":"Oh, K.-S. et al. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Commun. Signal. 22, 518 (2024).","journal-title":"Cell Commun. Signal."},{"key":"3885_CR37","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. HER2-low breast cancer: pathological and clinical landscape. J. Clin. Oncol. 38, 1951\u20131962 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Controlled Clin. Trials 17, 343\u2013346 (1996).","journal-title":"Controlled Clin. Trials"},{"key":"3885_CR39","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists Guideline update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3885_CR40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41591-024-02856-4","volume":"30","author":"MY Lu","year":"2024","unstructured":"Lu, M. Y. et al. A visual-language foundation model for computational pathology. Nat. Med. 30, 863\u2013874 (2024).","journal-title":"Nat. Med."},{"key":"3885_CR41","doi-asserted-by":"crossref","first-page":"103143","DOI":"10.1016\/j.media.2024.103143","volume":"94","author":"F H\u00f6rst","year":"2024","unstructured":"H\u00f6rst, F. et al. CellViT: vision transformers for precise cell segmentation and classification. Med. Image Anal. 94, 103143 (2024).","journal-title":"Med. Image Anal."},{"key":"3885_CR42","doi-asserted-by":"crossref","first-page":"101563","DOI":"10.1016\/j.media.2019.101563","volume":"58","author":"S Graham","year":"2019","unstructured":"Graham, S. et al. Hover-Net: simultaneous segmentation and classification of nuclei in multi-tissue histology images. Med. Image Anal. 58, 101563 (2019).","journal-title":"Med. Image Anal."},{"key":"3885_CR43","doi-asserted-by":"crossref","unstructured":"Gamper, J., Alemi Koohbanani, N., Benet, K., Khuram, A. & Rajpoot, N. in Digital Pathology (eds Reyes-Aldasoro C. C. et al.) 11\u201319 (Springer, 2019).","DOI":"10.1007\/978-3-030-23937-4_2"},{"key":"3885_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40218-9","volume":"14","author":"CD Gatenbee","year":"2023","unstructured":"Gatenbee, C. D. et al. Virtual alignment of pathology image series for multi-gigapixel whole slide images. Nat. Commun. 14, 4502 (2023).","journal-title":"Nat. Commun."},{"key":"3885_CR45","doi-asserted-by":"crossref","unstructured":"Le Bescond L., et al. Unsupervised nuclei segmentation using spatial organization priors. In Medical Image Computing and Computer Assisted Intervention (eds Wang, L. et al.) 325\u2013335 (Springer Nature Switzerland, 2022).","DOI":"10.1007\/978-3-031-16434-7_32"},{"key":"3885_CR46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"3885_CR47","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"3885_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3885_CR49","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"3885_CR50","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3885_CR51","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.17.00011 (2017).","DOI":"10.1200\/PO.17.00011"},{"key":"3885_CR52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s43018-022-00379-w","volume":"3","author":"K Krysiak","year":"2022","unstructured":"Krysiak, K. et al. A community approach to the cancer-variant-interpretation bottleneck. Nat. Cancer 3, 522\u2013525 (2022).","journal-title":"Nat. Cancer"},{"key":"3885_CR53","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-022-08357-3","volume":"23","author":"F Manders","year":"2022","unstructured":"Manders, F. et al. MutationalPatterns: the one stop shop for the analysis of mutational processes. BMC Genom. 23, 134 (2022).","journal-title":"BMC Genom."},{"key":"3885_CR54","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","volume":"51","author":"O Pich","year":"2019","unstructured":"Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732\u20131740 (2019).","journal-title":"Nat. Genet."},{"key":"3885_CR55","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & K\u00e4ller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"3885_CR56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"3885_CR57","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"3885_CR58","doi-asserted-by":"crossref","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289\u2013300 (1995).","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"3885_CR59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/bioinformatics\/btx560","volume":"34","author":"N Tern\u00e8s","year":"2018","unstructured":"Tern\u00e8s, N., Rotolo, F. & Michiels, S. biospear: an R package for biomarker selection in penalized Cox regression. Bioinformatics 34, 112\u2013113 (2018).","journal-title":"Bioinformatics"},{"key":"3885_CR60","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/bjc.2011.294","volume":"105","author":"F Farace","year":"2011","unstructured":"Farace, F. et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer 105, 847\u2013853 (2011).","journal-title":"Br. J. Cancer"},{"key":"3885_CR61","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1158\/1078-0432.CCR-19-1176","volume":"25","author":"E Pailler","year":"2019","unstructured":"Pailler, E. et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin. Cancer Res. 25, 6671\u20136682 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3885_CR62","volume":"5","author":"M Oulhen","year":"2021","unstructured":"Oulhen, M. et al. Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. npj Precis. Oncol. 5, 67 (2021).","journal-title":"npj Precis. Oncol."},{"key":"3885_CR63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41416-023-02535-0","volume":"130","author":"L Mezquita","year":"2024","unstructured":"Mezquita, L. et al. Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer. Br. J. Cancer 130, 682\u2013693 (2024).","journal-title":"Br. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03885-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03885-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03885-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:05:20Z","timestamp":1760623520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03885-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3885"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03885-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.P. has received consulting fees from AstraZeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal) and Daiichi Sankyo (institutional or personal); research funding (to the institution) from AstraZeneca, Daiichi Sankyo, Gilead, Seagen and MSD; and travel support from AstraZeneca, Pierre Fabre, MSD, Daiichi Sankyo and Pfizer. F.M. has received consulting fees from Novartis and Pegascy. M.L.T. has received consulting fees from AstraZeneca and Daiichi Sankyo. J.S.F. has received consulting fees, honoraria for lectures and presentations and support for attending meetings from and participation on data safety monitoring for AstraZeneca, GSK, Eisai, MSD, Lilly, Pfizer, Novartis, Daiichi Sankyo and Seagen. M.A.B. has received consulting fees from Daiichi Sankyo; honoraria for lectures and presentations from Exact Sciences; support for attending meetings from Novartis, Lilly and Seagen; and participation on data safety monitoring for MSD, AstraZeneca, Novartis, Lilly, Esai, Exact Sciences, Daiichi and Sankyo. T.B. has received grants or contracts from other entities, such as AstraZeneca (institution), Pfizer (institution), SeaGen (institution) and Novartis (institution); honoraria for lectures and presentations from SeaGen, Novartis, Pfizer and Lilly; support for attending meetings from Roche, AstraZeneca, Daiichi Sankyo, Pfizer and Novartis; and participation on data safety monitoring for AstraZeneca, Daiichi Sankyo, SeaGen, Novartis, Pfizer and Lilly. J.D. has received consulting fees from Daiichi Sankyo and AstraZeneca. A.S., F.S., L.L., D.W.S. and D.S. are employees of Daiichi Sankyo. S.M. is a data and safety monitoring member of clinical trials for IQVIA, Kedrion, Biophytis, Servier and Yuhan and a scientific committee study member of an observational study for Roche. F.A. has received research funding and speaker or advisor honoraria (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Eli Lilly. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}